Cruise ships, schools may become safer from viruses because of new patent

September 12, 2016, Kansas State University
Kyeong-Ok Chang, front, professor of diagnostic medicine pathobiology, and Yunjeong Kim, associate professor of diagnostic medicine pathobiology, in their laboratory at Kansas State University. Credit: Kansas State University

Outbreaks of stomach flu or noroviral gastroenteritis can easily occur in crowded quarters like cruise ships, army barracks and schools, but a recent patent may lead to antiviral drugs to help travelers, students, military personnel and others avoid infections.

Researchers at Kansas State University and Wichita State University have developed broad-spectrum antivirals that may help combat the infections and spreading of common viruses, such as noroviruses and rhinoviruses, and ones that pose a bioterrorism threat.

"The field of antiviral development is a growing area for many researchers because of better understanding of virus and compound synthesis," said Kyeong-Ok Chang, Kansas State University professor of diagnostic medicine and pathobiology and lead researcher on the antivirals. "As a virologist, to find means to treat patients and combat sicknesses is a dream come true."

The work of Chang; Yunjeong Kim, associate professor of diagnostic medicine and pathobiology at Kansas State University; and William C. Groutas, a distinguished professor of chemistry at Wichita State University, earned a patent issued to the Kansas State University Research Foundation, a nonprofit corporation responsible for managing technology transfer activities at the university. The research is federally funded by the National Institutes of Health.

"Antivirals are therapeutic tools, but you could also use them as a preventative measure if you expect to come into contact or if you are recently exposed to viruses, especially if you belong to high-risk groups because of pre-existing health concerns," Kim said. "That way, when you are exposed, you can have the antiviral in your system already."

The researchers' are unique because of their macrocyclic structures—spiral-shaped structures that don't break up easily in the bloodstream. Macrocyclic have characteristics for good stability in the patient's bloodstream, which is a critical aspect for any good drug.

"Macrocyclic compounds are kind of a big trend in antivirals or any drug development because of their highly stable nature in the body," Chang said.

In addition to structural strength for stability in the body, the compounds need to internalize inside of target cells where viruses multiply, as nearly all antiviral substances do, to inhibit viral growth. The patented compounds inactivate the viral enzyme produced during active replication in the cells.

"Like any drug development, potential compounds need to satisfy many additional requirements, including cell safety and stability, and eventual antiviral efficacy in the body," Chang said. "That's why it takes years to develop antivirals."

The compounds still must undergo several years of testing before they may be made available to consumers.

Explore further: Study identifies chemical compounds that halt virus replication

Related Stories

Study identifies chemical compounds that halt virus replication

March 21, 2013
Researchers at Boston University School of Medicine (BUSM) have identified a new chemical class of compounds that have the potential to block genetically diverse viruses from replicating. The findings, published in Chemistry ...

Virus spread can be blocked by attacking Ebola's Achilles' heel

August 24, 2016
Scientists have found Ebola's Achilles' heel: a new kind of chemical compound can block the protein Ebola uses to break out of cells and infect new cells. The compounds, revealed in a new paper in Bioorganic & Medicinal Chemistry ...

Research combats the stomach flu

December 5, 2013
More than 21 million cases of the stomach flu, caused by Norovirus, are reported every year in the United States.

Recommended for you

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.